Interleukin-1 beta (Interleukinum-1b)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Interleukins

Stimulators of hematopoiesis

Included in the formulation
  • Betaleukin®
    lyophilizate in / in PC 
    GosNII OCHB FMBA, FSUE     Russia
    • АТХ:

    L.03.A.C   Interleukins

    Pharmacodynamics:

    The drug stimulates hemopoiesis and early post-radiation recovery, has immunostimulating action and antiviral activity. The drug accelerates the recovery of stem potential and bone marrow hematopoiesis, especially granulopoiesis, after the damaging effects of cytostatics and ionizing radiation. This is due to his ability to initiate the entry of stem cells into the mitotic cycle and their mobilization into the blood, to increase the production of hematopoietic growth factors, to include mechanisms of general and local nonspecific resistance.

    Immunostimulating effect of the drug is realized by increasing the functional activity of neutrophilic granulocytes, induction of differentiation of precursors of immunocompetent cells, enhancing lymphocyte proliferation, activation of cytokine production and increasing antibody production.

    The drug has antiviral activity against hepatitis C virus due to direct action independent of interferon-alpha, using unique systems of activation of congenital antiviral immunity, induces the synthesis of endogenous interferon-alpha,and also promotes the elimination of the blocking effect of the hepatitis C virus on the biological activity of interferon-alpha. The systemic application of interleukin-1 beta is completely identical to that of the main endogenous inducer of the local inflammatory response and the systemic acute phase response. At the same time, due to the high purity of the drug, autoantibody formation is not observed.

    Pharmacokinetics:

    The period of semi-elimination of interleukin-1 beta in blood plasma with intravenous administration is 7.5 minutes. It is excreted unchanged through the kidneys, and with the bloodstream is evenly distributed in the organs and tissues.

    Indications:

    The drug is used as a stimulant leukopoiesis:

    - with toxic leukopenia of II-IV degree complicating chemo- and radiotherapy of malignant tumors, and as a protector of leukopoiesis, if necessary, chemotherapy under conditions of leukopenic background (the number of peripheral blood leukocytes is not less than 3 × 109/ l).

    As an immunostimulant:

    - secondary immunodeficiency conditions, developing after severe injuries, extensive surgical interventions;

    - purulent-septic and purulent-destructive processes;

    - infectious diseases;

    - chronic septic conditions.

    As a means of emergency anti-radiation therapy:

    - with acute emergency total and subtotal effects of ionizing radiation, not complicated by additional thermal exposure. The drug is used if the dose of radiation with an estimated estimate exceeds 1 Gy.

    The first detected pulmonary tuberculosis of a limited extent with prevalence of a productive type of tissue reaction (with destruction and without it) and pulmonary tuberculosis, in which the average sizes of productive foci in lung tissue and "residual cavities" are preserved for 4-5 months of treatment, regardless of the initial form of tuberculosis.

    For the treatment of patients with chronic viral hepatitis C, genotype 1, in the absence of a virologic response to primary antiviral therapy with pegylated or standard interferons and ribavirin

    ICD-10

    I.A15-A19.A15   Tuberculosis of respiratory organs, confirmed bacteriologically and histologically

    I.A30-A49.A40   Streptococcal septicemia

    I.A30-A49.A41   Other septicemia

    I.B15-B19.B18.2   Chronic viral hepatitis C

    III.D70-D77.D72.8   Other specified disorders of white blood cells

    III.D80-D89.D84.8   Other specified immunodeficiency disorders

    XIX.T66-T78.T66   Unspecified radiation effects

    Contraindications:

    Hypersensitivity.

    At patients in a stage of a septic shock and at the expressed fever.

    Pregnancy and lactation.

    Age to 18 years.

    Contraindications for prescribing the drug as an emergency anti-radiation therapy:

    - combined radiation-thermal damage;

    - feverish conditions;

    - severe hypotension;

    - shock.

    Contraindications for prescribing the drug in the treatment of tuberculosis:

    - the volume of lesions of more than 3 segments (including including foci of seeding),

    - presence of cavities of destruction more than 3 cm;

    - predominance of exudative tissue reaction in the lung tissue;

    - marked symptoms of intoxication, including hyperthermia.

    Carefully:

    No data.

    Pregnancy and lactation:

    The drug is contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously drip 15-20 ng / kg. For treatment of tuberculosis, the dose is 0.005 μg / kg.

    Immediately prior to administration, the contents of the ampoule are dissolved in 1 ml of a sterile 0.9% NaCl solution or water for injection and the total volume of the solution is adjusted to 100 ml with a 0.9% NaCl solution.The duration of administration can vary from 30 to 90 minutes. The course of treatment is 5 days. If necessary, similar repeated courses of treatment are carried out at intervals of 2 weeks.

    Side effects:

    Chilliness, gpain, giperthermia.

    Overdose:

    Not described.

    Interaction:

    Not described.

    Special instructions:

    Impact on the ability to manage motor transport and other technical devices

    Not found.

    Instructions
    Up